The CRISPR & Precision Genome Editing Series is dedicated to enhance the drug discovery and therapeutic applications of CRISPR/Cas9 editing by overcoming key specificity, efficiency and delivery challenges. Not only is the focus to enhance the basic research and drug discovery applications of CRISPR technology to elevate R&D productivity, but the series is committed to pioneer the translation of CRISPR technology into clinically effective CRISPR-based therapies. Join key industry leaders to learn how they are improving the very latest applications of CRISPR technology through advanced methodology, strategies and clinical timelines. Maximize the power of precision genome editing and fulfil its revolutionary potential.

Through industry-defining content, Hanson Wade events have built focused and senior level networks. We provide our highly valued sponsors more targeted business development, thought leadership and educational opportunities. Bespoke partnerships deliver not only a valuable onsite experience, but also year-round engagement & ultimately outstanding ROI . First time partnerships turn into long standing relationships that offer a genuine value year after year.

Overcoming patent expirations, replenishing clinical pipelines and increasing innovation are essential objectives for the pharmaceutical industry as they strive to deliver value for patients. Working with industry pioneers and key opinion leaders Hanson Wade delivers bespoke networking and solution-led conferences that help developers bring their innovations to market, establish mutually beneficial partnerships and realise the potential of precision medicine.